Tema Etfs LLC Boosts Stock Holdings in Exelixis, Inc. $EXEL

Key Points

• Tema Etfs LLC increased its holdings in Exelixis, Inc. by 45.2% in Q1, owning 71,496 shares, valued at approximately $2.64 million.
• Analysts have mixed views on Exelixis' stock, with a consensus price target of $44.06 and various buy ratings from firms like Truist Financial and Citigroup.
• Insider transactions were noted, including Director Sue Gail Eckhardt selling 18,838 shares, reflecting a 46.84% decrease in her ownership of the stock.

Tema Etfs LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 45.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,496 shares of the biotechnology company's stock after buying an additional 22,240 shares during the period. Tema Etfs LLC's holdings in Exelixis were worth $2,640,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. Nuveen LLC acquired a new stake in Exelixis in the 1st quarter valued at $123,310,000. Caisse DE Depot ET Placement DU Quebec increased its stake in shares of Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock worth $82,730,000 after purchasing an additional 1,907,167 shares during the last quarter. Invesco Ltd. increased its stake in shares of Exelixis by 40.2% during the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company's stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the last quarter. Jupiter Asset Management Ltd. increased its stake in shares of Exelixis by 233.4% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company's stock worth $51,698,000 after purchasing an additional 980,319 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in shares of Exelixis during the 4th quarter worth about $30,321,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Sue Gail Eckhardt sold 18,838 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $42.74, for a total transaction of $805,136.12. Following the transaction, the director directly owned 21,380 shares of the company's stock, valued at $913,781.20. This trade represents a 46.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total transaction of $324,683.15. Following the transaction, the director directly owned 358,882 shares in the company, valued at $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.82% of the stock is owned by corporate insiders.

Exelixis Stock Down 1.3%

Shares of EXEL stock traded down $0.48 during trading hours on Friday, hitting $37.42. 2,589,106 shares of the company's stock traded hands, compared to its average volume of 2,663,592. The stock's 50 day simple moving average is $41.26 and its 200 day simple moving average is $39.49. The stock has a market cap of $10.07 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 0.77 and a beta of 0.29. Exelixis, Inc. has a 12 month low of $25.12 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to analysts' expectations of $574.36 million. During the same period in the prior year, the company posted $0.84 earnings per share. Exelixis's revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on EXEL shares. Guggenheim reiterated a "buy" rating and issued a $45.00 price target on shares of Exelixis in a research note on Tuesday, July 29th. Zacks Research downgraded Exelixis from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 26th. Benchmark reiterated a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Royal Bank Of Canada dropped their target price on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating for the company in a research report on Tuesday, July 29th. Finally, Truist Financial reduced their price target on shares of Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Thirteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $44.06.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.